click below
click below
Normal Size Small Size show me how
Chapter 3 Pharm
Pharmacolgy
Term | Definition |
---|---|
Nervous system is divided into | Central Nervous System and Peripheral Nervous system |
Motor efferent section is divided into | Autonomic nervous system (involuntary) and Somatic nervous system (conscious activities) |
Nervous system | Sends signals through neurons or ganglion cells Uses neurotransmitters to cross synapses Somatic nervous system -nerve cell body originates in CNS Autonomic nervous system -interruption between CNS and innervation site |
Neurons and Ganglia | Preganglionic neurons- lead from vertebrae to synapse Postganglionic neurons- lead from synapse to organ or gland Multiple synapses occur in ganglia- drugs can have effect here |
Function and Anatomy of the ANS | Controls generally involuntary physiologic functions Two main divisions: parasympathetic and sympathetic Synapses occur in autonomic ganglia -sympathetic: most located near spinal cord -parasympathetic: most located near effector site |
Where is sympathetic located | near spinal cord |
Where is parasympathetic located | near the effector site |
Sympathetic division | Preganglionic neurons short Postganglionic neurons long |
Parasympathetic division | Preganglionic neurons very long Postganglionic neurons short |
Parasympathetic division Branches | Branches through cranial and sacral segments |
Sympathetic division Branches | Through thoracic and lumbar segments |
Multiple synapses occur in ganglia | Drugs can have effect here |
Neurotransmitters | Stored in nerve terminal Released with nerve impulse Diffuse across cleft, interact with receptors Either: Leads to production of electrical signals Causes physiologic changes in neuroeffector organ |
Acetylcholine (ACH) | Ganglionic synapse and neuroeffector site in parasympathetic system Ganglionic synapse in sympathetic system |
Norepinephrine (NE) | Neuroeffector site in sympathetic system |
Cholinergic agents | Affect ganglion, parasympathetic neuroeffector site, or muscular junction by stimulating ACH release |
Anticholinergic agents | Block ACH receptor or prevent ACH release |
Adrenergic agents | Stimulate receptor to release NE (adrenaline) |
Antiadrenergic agents | Block NE receptor from having effect |
General Physiologic Functions Controlled by the ANS | Parasympathetic and sympathetic divisions -innervate most organs (dual innervation) -usually have opposite effects |
The Sympathetic Nervous System | Generally dominant system when under stress Prominent when body in danger - fight or flight response -prolonged state can lead to death Adrenergic drugs -mimic sympathetic action, stimulate NE release |
The sympathetic nerve ending | Neurotransmitter is NE -synthesized in nerve ending -packaged in vesicles -released when impulse reaches nerve ending -combines with type of receptor present |
Methods of terminating physiologic effects of NE | Transport NE back into nerve terminal -repackaged into vesicles Diffuse NE away from site -ultimately metabolized by: monoamine oxidase catechol-0-methyl-transferase |
Presynaptic site in nerve ending | create false transmitters, block reuptake of NE, deplete NE from storage vesicles, increase NE release from nerve endings, block NE release from nerve terminals |
Postjunctional site where receptors are located | stimulate a-receptors, b-receptors, or both block a-receptors, or b-receptors |
Alpha-adrenergic drugs | stimulate a-receptor sites |
Beta-adrenergic drugs | stimulate b-receptor sites |
Neuronal activators | increase NE levels in nerve ending |
Alpha blockers | block a receptors |
Beta blockers | block b receptors |
Neuronal blockers | inhibit NE levels in nerve ending |
Alpha-Adrenergic Drugs | stimulate a receptor sites, include NE, epinephrine, and phenylephrine, vasoconstriction most dominant clinical effect, often administered intravenously, commonly referred to as vasopressors |
Alpha-Blocking Drugs | Block a receptor sites, create generalized, nonselective vasodilation, considered second-line antihypertensive, some specifically target bladder, prostate gland |
Beta-adrenergic drugs | Mainly stimulate B1-B2 receptors Used to treat: bradycardia by increasing heart rate/ heart failure by stimulating cardiac contractions |
Beta-Blocking drugs | Commonly used in clinical practice Many available: some affect b1 and b2 receptors, some relatively selective for b1-receptors Block effects of NE and epinephrine -decrease heart rate, force of heart contraction |
Adrenergic neuronal activators and blockers | decrease adrenergic nerve function. affect all sites where NE released, tend to influence a- and b-receptors, agents include reserpine, methyldopa, and clonidine |
Methylodopa | causes activation of receptor site by metabolite, stimulates centrally acting a2-receptors |
Clonidine | reduces sympathetic tone, and acts on cardiovascular center in brain stem |
Overall effects of the parasympathetic division | Dominant when body at rest Controls and stimulates: -digestion -waste elimination -genitourinary system Cardiovascular system generally decreased |
ACH | synthesized nerve ending, packaged in vesicles, nerve impulse stimulates combination with receptor |
Acetylcholinesterase (ACHE) | Enzyme that metabolizes excess ACH |
Cholinergic Receptors | Five muscarinic receptors (M1-M5) -throughout body Nicotinic-1 (N1) -All ANS ganglion sites Nicotinic-2 (N2) -neuromuscular junctions in somatic nervous system |
Mechanism of action of cholinergic drugs | Broader spectrum of unwanted side effects Possible drug-receptor interactions: -stimulate muscarinic receptor, producing cholinergic effect -block cholinergic receptors, prevent ACH interaction -block ACHE, enhancing duration of parasympathetic impul |
Choline esters | Stimulate muscarinic receptors |
Anticholinesterases | Block the ACHE enzyme |
Anticholinergics | Block ACH receptor sites |
Antimuscarinics | Block muscarinic receptor sites |
Anticholinesterase Drugs/ Cholinesterase Inhibitors | inhibit ACHE effects/ cause prolonged, intensified ACH effects/ Long-term use may cause: muscle weakness, diarrhea, excess salivation, excess bronchial secretions/ limited therapeutic use |
Anticholinergic Drugs | block muscarinic receptors, high doses can affect nicotinic receptors, indication depends on specific receptors |